Dako and Amgen to collaborate in development of a companion diagnostic for an Amgen investigational cancer therapy
(Thomson Reuters ONE) -
Dako, a world leading independent cancer diagnostic supplier with 45 years of
experience in pathology, announced today that it has entered into a development
and collaboration agreement with Amgen Inc. (Nasdaq: AMGN) to develop a
diagnostic test for an Amgen cancer drug candidate targeted for a rare and
deadly cancer.
"I am proud to announce that Dako and Amgen have succeeded in putting together a
business model that supports the concurrent development of drug and diagnostics
for a low incidence cancer - something that has been difficult to achieve in the
industry until now," says Lars Holmkvist, Dako's chief executive officer.
"This new collaboration brings hope to cancer patients suffering from this rare
form of cancer," he adds.
Today's announcement marks the continuation of Dako's commitment to advance
companion diagnostics by collaborating with strong partners in the
pharmaceutical sector. Over the past 24 months agreements with AstraZeneca,
Bristol-Myers Squibb and Genentech have been announced.
"Our agreement with Amgen is one of several partnerships that Dako has entered
with pharma companies to enable the development of diagnostic tests to predict
which patients are most likely to respond to specific treatments," says Lars
Holmkvist.
The demand for personalized medicine is increasing with the recognition that it
may provide a way to improve patient care and manage healthcare costs by
targeting treatments to individuals more likely to benefit from specific
therapies.
About Dako
Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics.
Hospital and research laboratories worldwide use Dako's know-how, reagents,
instruments and software to make precise diagnoses and determine the most
effective treatment for patients suffering from cancer. Employing more than
1000 people and being present in more than 80 countries, Dako covers essentially
all of the anatomic pathology markets globally. Dako is owned by private equity
fund EQT.www.dako.com
Media contact
Maia Fredtoft Søchting
Corporate Communications
Dako Denmark A/S
Tel. +45 25 46 10 83
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE
[HUG#1576339]
Unternehmensinformation / Kurzprofil:
Datum: 10.01.2012 - 15:00 Uhr
Sprache: Deutsch
News-ID 102760
Anzahl Zeichen: 2945
contact information:
Town:
Glostrup
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 156 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dako and Amgen to collaborate in development of a companion diagnostic for an Amgen investigational cancer therapy"
steht unter der journalistisch-redaktionellen Verantwortung von
Dako Denmark A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
